drugset / Trial / NCT00529516
Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Non-randomizedParallel-groupDouble-blindPrevention
Summary
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this observer blind study, the subjects previously enrolled in study 104888 (NCT00377585) will receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in study 104888 (NCT00377585) are eligible for participation in this study.
Timeline
- Start
- 2007-10-15
- Primary completion
- 2007-12-21
- Completion
- 2008-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK576389A | Vaccine | — | Intramuscular |
| Comparator | Influenza Virus Vaccine | Vaccine | — | Intramuscular |